GREENLAND MINES LTD Marketable Securities, Unrealized Gain (Loss)
GREENLAND MINES LTD (GRML) reported Marketable Securities, Unrealized Gain (Loss) of $3.36 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-17.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2024-04-17
- GREENLAND MINES LTD marketable securities, unrealized gain (loss) for the quarter ending 2023-12-31 was $509.92K, a 57.43% decline year-over-year.
- GREENLAND MINES LTD marketable securities, unrealized gain (loss) for the quarter ending 2023-09-30 was $741.83K, a 137.61% increase year-over-year.
- GREENLAND MINES LTD marketable securities, unrealized gain (loss) for the quarter ending 2023-06-30 was $862.22K, a 488.96% increase year-over-year.
- GREENLAND MINES LTD marketable securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $451.55K.
- GREENLAND MINES LTD marketable securities, unrealized gain (loss) for fiscal 2023 was $3.36M, a 103.08% increase from fiscal 2022.
- GREENLAND MINES LTD marketable securities, unrealized gain (loss) for fiscal 2022 was $1.66M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $509.92K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | $1.25M derived: sum of 2 quarters · filed 2024-04-17 | $2.11M derived: sum of 3 quarters · filed 2024-04-17 | $3.36M 10-K · filed 2024-04-17 | |
| 2023-09-30 | $741.83K 10-Q · filed 2023-11-17 | $1.60M derived: sum of 2 quarters · filed 2023-11-17 | $2.85M 10-Q · filed 2023-11-17 | $3.25M derived: sum of 4 quarters · filed 2024-04-17 | |
| 2023-06-30 | $862.22K 10-Q · filed 2023-08-21 | $2.11M 10-Q · filed 2023-08-21 | $2.51M derived: sum of 3 quarters · filed 2024-04-17 | $2.82M derived: sum of 4 quarters · filed 2024-04-17 | |
| 2023-03-31 | $451.55K 10-Q · filed 2023-05-24 | $1.65M derived: sum of 2 quarters · filed 2024-04-17 | $1.96M derived: sum of 3 quarters · filed 2024-04-17 | $2.11M derived: sum of 4 quarters · filed 2024-04-17 | |
| 2022-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | $1.51M derived: sum of 2 quarters · filed 2024-04-17 | $1.66M derived: sum of 3 quarters · filed 2024-04-17 | $1.66M 10-K · filed 2024-04-17 | $375.98K 10-K · filed 2023-04-10 |
| 2022-09-30 | $312.20K 10-Q · filed 2023-11-17 | $458.60K derived: sum of 2 quarters · filed 2023-11-17 | $458.60K 10-Q · filed 2023-11-17 | ||
| 2022-06-30 | $146.40K 10-Q · filed 2023-08-21 | $146.40K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |